Exercise in Air Pollution and Lung Health in Asthmatics
The Effects of Inhaled Beta-2-Agonists and Air Pollution on Lung Function and Athletic Capacity
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Verwacht)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z1
- University of British Columbia, Environmental Physiology Laboratory
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- mild-moderate asthmatics with controlled treatment (definition of "mild": percent fall index at eucapnic voluntary hyperpnea (EVH) test on screening day between 10-15%; "moderate": percent fall index at EVH test on screening day between 15 - 20%).
- men and non-pregnant women
Exclusion Criteria:
- any history of uncontrolled respiratory or cardiac disease
- pregnancy
- allergic reactions to lidocaine and salbutamol
- any recent infections or orthopaedic nasal issues/injuries that may interfere with the insertion of the catheter needed to assess expiratory flow limitation or work of breathing
- claustrophobia in small rooms, comparable to the air pollution chamber used for this study.
- English as a second language (ESL) - participants who are not able to understand the risk that may be associated with the participation in this study due to language difficulties after following the University of British Clinical Research Ethics Board Guidance Notes 13.2.1. (ESL participants will be given a consent form in the most appropriate language or an appropriate translator will be present during the initial consent process).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Actieve vergelijker: Resting in diesel exhaust following salbutamol inhalation
Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Participants will be exposed to PM2.5 of 300 μg/m3
|
|
Placebo-vergelijker: Resting in diesel exhaust following placebo inhalation
Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Participants will be exposed to PM2.5 of 300 μg/m3
Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
|
|
Actieve vergelijker: Cycling in diesel exhaust following salbutamol inhalation
Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
|
Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Participants will be exposed to PM2.5 of 300 μg/m3
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
|
|
Placebo-vergelijker: Cycling in diesel exhaust following placebo inhalation
Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
|
Participants will be exposed to PM2.5 of 300 μg/m3
Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
|
|
Sham-vergelijker: Resting in filtered air following salbutamol inhalation
Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Participants will be breathing filtered air
|
|
Placebo-vergelijker: Resting in filtered air following placebo inhalation
Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Participants will be breathing filtered air
|
|
Sham-vergelijker: Cycling in filtered air following salbutamol inhalation
Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
|
Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
Participants will be breathing filtered air
|
|
Placebo-vergelijker: Cycling in filtered air following placebo inhalation
Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
|
Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
Participants will be breathing filtered air
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change in rating of perceived exertion for breathing, dyspnea
Tijdsspanne: Difference in perceived dyspnea between salbutamol and placebo exposure as well as polluted air and filtered air. Dyspnea ratings will be collected every 2.5min for a duration of 45min during the exercise test.
|
Difference in perceived dyspnea between salbutamol and placebo exposure as well as polluted air and filtered air. Dyspnea ratings will be collected every 2.5min for a duration of 45min during the exercise test.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change in work of breathing (WOB) between filtered air and polluted air
Tijdsspanne: work of breathing will be assessed every 2.5min for a time period of 45min during the exercise bout
|
work of breathing will be assessed every 2.5min for a time period of 45min during the exercise bout
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in spirometry (FEV1 and FVC) between filtered air and polluted air
Tijdsspanne: Spirometry will be assessed at baseline and 45min after the start of the exercise bout.
|
Spirometry will be assessed at baseline and 45min after the start of the exercise bout.
|
|
|
Change in cognitive function
Tijdsspanne: Cognitive function will be assessed at baseline (prior to entering the air pollution chamber) and 45 min after the start of the exercise intervention.
|
cognitive function will be assessed using the NIH toolbox tests and the brain derived neurotrophic factor (BDNF) blood serum measurements
|
Cognitive function will be assessed at baseline (prior to entering the air pollution chamber) and 45 min after the start of the exercise intervention.
|
|
Retinal Imaging
Tijdsspanne: The retina will be imaged at baseline (prior to entering the air pollution chamber) and 20 min after the completion of the exercise intervention.
|
The blood vessels in the eye will be imaged using a camera.
|
The retina will be imaged at baseline (prior to entering the air pollution chamber) and 20 min after the completion of the exercise intervention.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Fysiologische effecten van medicijnen
- Adrenerge middelen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Autonome agenten
- Agenten van het perifere zenuwstelsel
- Adrenerge agonisten
- Bronchusverwijdende middelen
- Anti-astmatische middelen
- Agenten van het ademhalingssysteem
- Reproductieve controlemiddelen
- Adrenerge bèta-2-receptoragonisten
- Adrenerge beta-agonisten
- Tocolytische middelen
- Albuterol
Andere studie-ID-nummers
Andere studie-ID-nummers
- H13-01079
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .